2026 Volume: 02 Issue: 05 www.ijrpa.com ISSN 2456-9995 Review Article

International Journal Research Publication Analysis

Page: 01-12

"COMPREHENSIVE REVIEW ON THE MANAGEMENT AND PREVENTION OF ADVERSE DRUG REACTIONS IN CLINICAL PRACTICE"

*Manish Samyal, Taniya Chaudhary, Dr. Nitin Kumar

Saraswathi College of Pharmacy, Pilkhuwa, hapur (UP).

Article Received: 02 April 2026
Article Revised: 22 April 2026
Published on: 12 May 2026

***Corresponding Author: Manish Samyal**
Saraswathi College of Pharmacy, Pilkhuwa, hapur (UP).

DOI: https://doi-doi.org/101555/ijrpa.9358

ABSTRACT

A bad reaction to medicine happens when someone gets hurt by a drug meant to help. Worldwide, experts agree it's harm that wasn't planned during treatment. Sometimes these effects come out even when doses are correct. Not every negative effect means danger, but some need quick care. Problems tied to drugs add stress on hospitals and clinics. Yet many of them could be avoided with better systems in place. How doctors and nurses handle reactions differs quite a bit across regions. One reason might be gaps in how training is delivered. Another factor could involve unclear rules or mixed messages at work sites. Fixing this may depend less on new tools, more on smarter learning plans. Teaching teams well might lift both speed and accuracy in reporting issues. Better records often follow when staff truly understand what to watch for. Improvements here tend to spread once trust builds around sharing mistakes. Still, progress moves slow if support stays uneven between departments. Clearer routines plus steady guidance often lead to fewer repeated errors. When people feel safe speaking up, problems get caught earlier. Learning together changes habits more than warnings ever do.

ADR draws broad backing for being straightforward, adaptable, quick, less expensive when settling disputes, also easing pressure on courts. Yet here, the view tilts skeptical - focus lands on risks and drawbacks. Peeling apart standard civil procedures then lining them beside ADR's traits shapes what comes next. Balance tips between gains and losses get laid bare. Outcome? ADR might weaken traditional court paths instead of standing alongside as choice. Still, Sweden's latest push for two court-linked ADR models could bring real value - if handled right.

Owing to the consummate significance of monitoring, managing, and precluding ADRs in assuring health benefits, perfecting trust in medicine non supervisory authorities, gaining acceptance of new medicine blessings, promoting Out of nowhere, detailed checking in patient files ties into how info gets shared through team-based learning setups. Suddenly, hospital and neighborhood pharmacists step in, linking doctors with real-world examples inside drug reaction tracking efforts.

1. INTRODUCTION

Strange reactions to medicines show up when someone gets a dose meant for treatment, yet harm happens anyway. These effects come from how the drug works inside the body, not because it was used wrong. Experts sort these events using Rawlins' method - splitting them into two main kinds based on what goes on beneath the surface. One group follows predictable patterns; another arrives without warning. Mistakes like giving the wrong medicine, bad timing, ignoring allergies, or skipping checks can lead to avoidable issues. Watching for such problems falls under pharmacovigilance - a broad idea covering many steps. It includes spotting unwanted outcomes, gathering facts, making sense of them, plus shaping rules that protect people. This process ties closely to health efforts worldwide, forming a steady base for safer care.

Every now and then, bad reactions pop up in clinics, behind three to five out of every hundred hospital entries among grown-ups and kids alike. About ten to seventeen percent of patients getting care run into one of these events during treatment. Landing in the hospital because of such a reaction makes it more likely to happen again later on down the line. People hit by these incidents face over ten times the risk of dying compared to others who stay clear. Time spent inside hospitals often stretches twice as long when trouble shows up, sometimes piling past twenty days without warning. Long-term physical and mental health struggles can follow serious reactions (13, 14). Healthcare spending in the U.S. sees a burden beyond 30 billion dollars yearly due to adverse effects (8). AU$1.2 billion marks Australia’s estimated recurring expense from medicine-linked hospital stays - though nearly half these cases might never happen with proper steps taken (9, 15).

In lively medical centers like hospitals, side effects get noticed and sent to safety watchdogs by health workers - doctors, pharmacists, nurses (16, 17). Most of these reports come in freely, a method often called spontaneous reporting. Evidence shows it's an affordable way to catch fresh, meaningful warnings about drug reactions (18).

Many rules aim to boost awareness among health workers about how serious side effects can be. Because they care for patients, these professionals must share every time a medicine causes harm. The World Health Organization supports this through its guide on Medicine Safety, which outlines ways to watch, judge, tell, and teach others about bad reactions - useful everywhere around the world. Each nation shapes its own way of handling reports; guidance exists across different medical environments. For instance, in Australia, the Therapeutic Goods Administration demands alerts when new medicines cause suspected problems. This includes any unknown reaction, even if it hasn't been seen before, plus cases where drugs may have led to severe outcomes such as lasting damage or loss of life.

Even with good guidelines in place, how ADRs are handled still depends a lot on human choices, leading to big differences in real-world medical practice. Reports often miss key details because of where health care providers work - location shapes what gets recorded (20). What kind of reaction is reported, along with how precise and complete the information turns out, changes based on provider background and workplace setting (21). Judging an ADR correctly takes specific skills: knowing basic drug and immune system behavior helps, just like gathering full patient histories, tracking medicine timing closely, doing personal evaluations, while also ruling out other possible causes (5). When reactions happen in complicated cases, mistakes in judgment may hide the actual problem drug, yet blaming the wrong one might push people away from useful treatments without reason. Faulty analysis doesn't only affect individual care - it shakes trust in medication safety overall, weakening efforts to monitor drugs after they reach the public.

One thing stands clear: each sanitarium must run an active ADR system. Beyond equipment, steady attention to vital signals plays a role too. Inside every facility, setting up a way to manage adverse reaction reports becomes necessary, while also revisiting markers that help track progress over time. Keeping these procedures consistent narrows gaps in how care is delivered, possibly lifting safety levels for those receiving treatment. Signs worth watching might involve how often reactions get reported, what kind of events appear, who responds, plus whether entries follow required formats. Truth is, counting reports comes easily; judging their depth or usefulness poses more challenge. How complete a report appears often shows how well health providers understand the link between medicine and effect, including enough medical detail to make sense of cause. Skill level, training, hands-on exposure, along with awareness of subtle reasoning rules in causality judgments, shape much of a report's value. Sharing verified risks clearly - both with patients and fellow clinicians after an incident - adds another layer to what counts as strong practice

Bracket OF ADVERS Emedicine responses

A D R Types Include A and B With Additional Classes Recently Added.

Happening often, type A reactions come from strong versions of a drug's usual effects when given at regular doses. They show up reliably, follow clear patterns, happen with expected frequency, plus carry low risk of death. Opioids slowing breathing is one example; another involves warfarin leading to blood loss. Liver harm triggered by certain drugs appears regularly, especially if too much acetaminophen gets used. Skin reacting badly in sunlight pops up sometimes with specific antibiotics, while teeth turning yellow links closely to tetracycline use. Kidney damage tags along with some powerful infection fighters like aminoglycosides. Stomach pain, ulcers forming, internal bleeding join the list too - common after long-term NSAID intake. Even side effects not tied directly to a medicine's main job appear here: think mouth drying out on tricyclics meant for mood shifts.

Odd reactions pop up even when a drug works as expected. Though rare, these effects show only after long use. An allergy strikes suddenly - say, breathing trouble from penicillin. Some people react badly under anesthesia, their body overheating without cause. Others handle common drugs poorly - beta-lactams, tetracyclines, HIV treatments - just can't tolerate them. A few suffer liver harm from medicines like carbamazepine or isoniazid. The immune system sometimes misfires: vancomycin, fluoroquinolones trigger rash or worse. Chloramphenicol may wipe out blood cells. Rifampicin joins isoniazid in harming the liver, though not always fast. Each case stands apart - one person, one strange outcome.

Some side effects stick around long after they first show up. Take bisphosphonates, which can lead to jaw bone damage over time. Another example: corticosteroids quietly dulling hormone activity in glands far down the line. These reactions unfold slowly, lingering well beyond initial exposure. (25).

Later reactions sometimes show up long after treatment ends. These responses creep in slowly, making them tough to spot at first. Some blood changes may emerge weeks later - leucopenia following lomustine is one case. Movement issues might appear much later, like tardive dyskinesia from older antipsychotics. Birth differences have been tied to certain seizure drugs used during pregnancy. Harmful cell growth has also linked to immune dampeners over time.

Stopping certain medicines suddenly can trigger reactions. Withdrawal might spark alertness, tension, or altered senses when ending benzodiazepines. Heart issues may arise once beta blockers are discontinued. Symptoms often surface when painkillers or sedatives are abruptly

stopped. Such patterns reflect how the body reacts to abrupt cutoffs. These effects link directly to unplanned exits from drug regimens.

Medicine might stop working as expected. This kind happens when treatment fails in surprising ways. Dialysis can wash out a drug, making it less effective. Plasmapheresis does something similar by removing substances from blood. Sometimes drugs interact and change how fast the body breaks them down. When metabolism shifts, the medicine may not work right. These cases show how therapy effects fade unexpectedly

2. Threat FACTORSOFADVERS Emedicine response

Age(childrenandoldpeople)

Multiplemedicineremedy

formerhistoryof ADR

Alteredphysiology

inheritablecomplaint

Multipleco morbidconditions

Hormonal factors influence adverse drug reactions through estrogen progesterone testosterone thyroid hormones cortisol insulin and growth hormone.



Image: ADR Risk Factors

Polypharmacy andmedicinerelations

Axesofage(babesandsenior)

Renal or Hepatic Impairment

inheritablefactorsaffectingmedicinemetabolism

HistoryofdisinclinationsorformerADRs

habitualconditionssimilaras diabetes orheartfailure

Wayin the operation of ADRs

Spotting side effects early keeps care on track. Watch closely when treating older patients, people taking many medicines, or those already unwell. Suspicion should rise without delay in these cases. One way to check links uses Naranjo's method. Another relies on standards from WHO-UMC. Figuring out if a drug caused harm often leans on such systems. Clarity comes easier with structured reviews. Rarely does one clue give it away - patterns matter more. Guessing won't help; weighing evidence will. These steps anchor sound judgment in messy situations.

Watch for swelling or skin reactions when beginning ACE inhibitors.

From the start, figure out if the medicine actually led to the unwanted effect. Look closely at when the drug was given compared to when symptoms appeared. After that, stop the treatment - watch whether things get better once it is gone. Later on, giving it again might show the same reaction returning. How rigid or unchanging the symptom appears matters too. Tools that rate intensity help sort cases into Mild, Moderate, or Severe groups. When health risks shift life drastically, they land in the Severe category.

Separating mild stomach issues from serious bleeding due to NSAIDs.

Right away, act based on how severe things are - halt the drug causing trouble or adjust the treatment plan. When reactions stay light, cutting down dosage or swapping in a necessary alternative might do just fine. Usually, pick remedies that ease ADR discomfort directly. For slight allergic signs like skin irritation or itchiness, antihistamines often help quiet it down. Bad cases such as anaphylactic shock need epinephrine plus steroid drugs without delay. If chemo brings sickness and throwing up, anti-nausea meds come into play. With loose bowels draining body fluids, replacing water and minerals becomes key.

Immediate heparin stop and alternative anticoagulant use required in heparin-induced thrombocytopenia.

Spotting risks early means looking at things like family history, drug allergies, liver or kidney issues, also interactions between medicines. People taking meds should learn about possible reactions - knowing signs to notice plus moments needing a doctor. Some drugs, such as abacavir or warfarin, work better when genetic tests guide choices up front.

Genetic test for HLA-B5701 before abacavir use.

Checking patients closely matters most when they take risky medicines, especially if past reactions happened. Because of this, staying in touch helps confirm what happens after someone reacts, even when treatment stops or something else begins instead. Watchfulness stays key through every step, since outcomes can shift without warning. Those who've reacted before need extra attention simply due to their history. Follow-up isn't automatic - it depends on how things unfold case by case.

Regular monitoring of liver thyroid and lung function needed with long term amiodarone use.

Start reporting adverse drug reactions through global or national pharmacovigilance networks, like the WHO's International Drug Monitoring initiative or the U.S. FDA's MedWatch system. Systems that automate alerts build up records on possible medication effects - this reveals recurring issues across large groups. Watching these signals closely allows experts to spot shifts over time without delay.

A sketch shows someone reporting Stevens-Johnson syndrome after taking a fresh antibiotic, shared with a drug safety tracking effort to help shape understanding about risks during pregnancy.

Negotiating Alternatives When Essential Medicines Cause Adverse Effects.

Using COX-2 inhibitors instead of traditional NSAIDs when gastrointestinal risks are present to lower chances of GI bleeding.

Unborn developments

Down the road from here, details emerge about what happens inside the WHO's watchful eyes in Uppsala. This effort links hands with Europe's team focused on medicine safety, letting experts across nations join forces on shared drills. Such moves could quietly open doors to sharper global detection of hidden drug risks. Coming up next for the program: smarter math networks that sift through mountains of records, aiming to spot unknown dangers tied to treatments before they spread. Upgrades are also due for how plant-based cures get classified. Ties strengthen with groups chasing early warnings - one studies patterns in drug effects, another gathers medical traditions worldwide into joint efforts. A fresh chapter unfolds in clinical science, where tiny biological clues offer glimpses into illness roots at deeper levels than ever. Mapping human genes helps foresee who might fall ill under certain conditions. How drugs behave in bodies becomes clearer when hereditary traits shaping their journey come to light. Right now, physical signs and DNA checks already hint at metabolic hiccups ahead. More gene tools on the horizon may predict treatment outcomes,

even unwanted reactions, raising hopes for tailored care. With each new layer of data on how people react to medicines, remember this hard truth stays fixed: nearly every second harm caused by drugs stems from mistakes that could have been skipped.

Pharmacist Involvement in Reporting and Managing ADRs

A patient's primary point of contact with the healthcare system both before and throughout drug therapy is a pharmacist. ADRs in health systems can be better designed and implemented with the assistance of pharmacists, who are particularly suited to offer useful information about medication products, examine adverse events, and assist in designing and implementing system improvements. Emphatically, pharmacists play a quintessential role pivotal to identifying, assessing, strategically planning management, resolving, and preventing ADRs, and can be further enhanced through education and training of one's self as well as patients.86-89 Notwithstanding this, it is equally important to emphasize the importance of regularly monitoring and reporting ADRs, particularly among clinical and community pharmacists. The pharmacist should facilitate the following activities, such as (i) analyzing each reported ADR, (ii) identifying drugs and patients at high risk associated with ADRs and adverse events, (iii) the development of scope, policies and procedures for the ADR monitoring and reporting programs, (iv) description of the responsibilities and interactions of pharmacists with clinicians, nurses, risk managers, and other healthcare professionals in the ADR programs, (v) making academic and promoting self- and patients' educational use of the ADR programs, and (vi) collecting appropriate data to create, preserve, and- regularly assess ADR records and databases including use of uniform reporting rates and tracking the frequency of ADR incidents regionally, nationally, and globally, (vii)sharing information to regulatory authorities and public health departments nationally and globally, (viii)application of data acquired by the ADR program in signal detection and evaluation, (ix) creating and managing databases throughout the organization- and across the nations, (x) developing risk evaluation, mitigation and minimization strategies, (xi) promoting awareness and education on rational drug use and ADRs, and (xii)facilitating the reporting of serious or unexpected ADRs86-A patient's primary point of contact with the healthcare system both before and throughout drug therapy is a pharmacist. ADRs in health systems can be better designed and implemented with the assistance of pharmacists, who are particularly suited to offer useful information about implementing system improvements.

PREVENTION OF AN ADVERSE DRUG REACTION

Stopping bad reactions to drugs means skipping treatments for people more likely to suffer, or those where medicine brings bigger risks - sometimes combining medications helps lower harm, watching outcomes closely matters too. Reports piling up through systems like the UK's Yellow Card back up hunches about drug troubles being real; still, most incidents go unrecorded no matter where care happens. When in doubt, sending in a note makes sense. These drug-linked problems wear many masks, often looking exactly like regular illnesses, showing up anywhere in the body. Patients stuck in hospitals face varied medication issues - tiredness dragging them down, odd shifts in blood or chemistry labs pointing to kidney strain, messed-up minerals, low red cells, gut bleeds, sugar dropping too far, depending on age or unique groups like kids, pregnant women, older adults, poor choices in handing out pills, especially antibiotics used wrong, losing punch because bugs resist them, trips to ER tied to meds, returns after discharge linked to prescriptions, plus infections picked up during care, say C. difficile creeping in Most times, avoiding a bad reaction starts with spotting which patients might react poorly. That group often needs a different approach right away. One way shifts the method based on who could struggle. Another path checks whether risks are reduced ahead of time. Besides these moves, medical workers usually keep a close eye (i)avoid and be vigilant of high-risk drugs114,116,125, Stop using medications that aren't needed or make little sense119,136,127, (iii)consider drugs as a cause of any newsymptom (iv)Identify irrational use (misuse, overdose, drug abuse, over the counter use, self-medication)Wrong way to give medicine spotted here instead Watch for when several medicines are taken together, especially those from the same type of treatment, along with drinking alcohol Side effects shouldn't be managed by adding a second medication, since that often results in using medicines without real need (viii)Identify and avoid potential risk of drug-drug interactions For older patients, tweak the dose depending on how well their liver and kidneys work. When liver activity slows, changes are needed. Kidney performance matters just as much. Watch calcium or potassium levels closely. If minerals shift out of range, adapt accordingly. Age alone isn't the only factor. Organ health plays a strong role. Balance guides adjustments more than numbers do (x)Risbarriers to medication adhere and address medication non-adherence

CONCLUSION

A close look at ADRs covers who reports them and how it happens. Reporting flows from patients and doctors alike toward regulatory bodies. Understanding today's system means tracking where information begins India runs a system called pharmacovigilance, tracking how drugs affect people. This setup looks closely at adverse reactions after medicines are used. Instead of waiting, it collects reports from many sources across health centers. Doctors, nurses, even patients share what they see. Information flows into central units where experts review each case. These teams decide if a drug might be causing harm. National guidelines shape how data is gathered and checked. Safety updates then reach hospitals and clinics nationwide. Oversight comes from official groups that meet regularly. Their role? To study patterns, spot risks early. Every level of care takes part, rural to urban. Progress shows in stronger response systems over time Talks often touch on these points. Because so many people live in India, checking medicine safety becomes essential. Across such a vast country, medicines are taken everywhere, which complicates tracking side effects. Different kinds of medications serve different needs, adding layers to oversight. Age differences plus cultural diversity shape how treatments are used. Watching for reactions grows harder when so many variables mix together. Even so, India runs a carefully set up system to track drug reactions. City people tend to know more than those living in villages; information spreads further when outreach programs keep going. Taking many kinds of medicines across age and cultural lines makes oversight harder. Still, the country maintains an orderly process for spotting side effects. Town residents usually understand more than villagers do - repeated public messages help close the gap. One way to tackle tough problems in India's crowded clinics means paying close attention to what holds things back. Working around limits calls for smart planning, practical fixes that do not cost too much, yet still matter where doctors are few and patients many. Shifting how people think begins with teaching, spreading knowledge slowly over time. Change takes root when habits evolve, not overnight, but step by steady step. Better tracking of drug reactions becomes possible once attitudes shift along with actions. Decisions start relying on proof, shaped by real reports instead of guesses. Patient safety grows stronger when systems learn to listen, adapt, respond. What matters most shows up not in grand plans but quiet persistence.

REFERENCES

1. Australian Government, Department of Health, Therapeutic Goods Administration (2019) Reporting adverse events. [cited 2020 Nov 30]
2. Thien FCK (2006) 3. Drug hypersensitivity. Med J Aust 01 Sept 2006 185(6):333–338
3. Wolfe D, Yazdi F, Kanji S, Burry L, Beck A, Butler C et al (2018) Incidence, causes, and consequences of preventable adverse drug reactions occurring in inpatients: a systematic review of systematic reviews. PloS One 13(10):e0205426
4. Organization WH (2019) Medication safety curriculum guide. [cited 2020 Nov 20]
5. Organisation WH (2002) Safety of medicines – a guide to detecting and reporting adverse drug reactions – why health professionals need to take action
6. Bouvy JC, De Bruin ML, Koopmanschap MA (2015) Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf 38(5):437–453
7. Impicciatore P, Choonara I, Clarkson A, Provasi D, Pandolfini C, Bonati M (2001) Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 52(1):77–83
8. Sultana J, Cutroneo P, Trifirò G (2013) Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother 4(Suppl 1):S73–S77
9. Roughead EE, Semple SJ, Rosenfeld E (2016) The extent of medication errors and adverse drug reactions throughout the patient journey in acute care in Australia. Int J Evid Based Healthc 14(3–4):113–122
10. Miguel A, Azevedo LF, Araújo M, Pereira AC (2012) Frequency of adverse drug reactions in hospitalized patients: a systematic review and meta-analysis. Pharmacoepidemiol Drug Saf 21(11):1139–1154
11. Nair NP, Chalmers L, Bereznicki BJ, Curtain CM, Bereznicki LR (2017) Repeat adverse drug reaction-related hospital admissions in elderly Australians: a retrospective study at the Royal Hobart Hospital. Drugs Aging 34(10):777–783
12. Davies EC, Green CF, Taylor S, Williamson PR, Mottram DR, Pirmohamed M (2009) Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One 4(2):e4439
13. Baiardini I, Gaeta F, Molinengo G, Braido F, Canonica GW, Romano A (2015) Quality-of-life issues in survivors to anaphylactic reactions to drugs. Allergy 01 Jul 2015 70(7):877–879
14. Lorimer S, Cox A, Langford N (2011) A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting. J Clin Pharm Ther 18 May 2011 37:148–152
15. Caplan LR (2001) Evidence based medicine: concerns of a clinical neurologist. J Neurol Neurosurg Psychiatry 71(5):569

16. Van Grootheest A, Van Puijenbroek E, de Jong–van den Berg L (2002) Contribution of pharmacists to the reporting of adverse drug reactions. Pharmacoepidemiol Drug Saf 11(3):205–210
17. Gedde-Dahl A, Harg P, Stenberg-Nilsen H, Buajordet M, Granas AG, Horn AM (2007) Characteristics and quality of adverse drug reaction reports by pharmacists in Norway. Pharmacoepidemiol Drug Saf 16(9):999–1005
18. Aagaard L, Hansen EH (2009) Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics SSRIs and NSAIDs. BMC Clin Pharmacol 9(1):1–14
19. Department of Health TGA (2020) Reporting adverse events. [cited 2020 6 Nov]
20. Lopez-Gonzalez E, Herdeiro MT, Figueiras A (2009) Determinants of under-reporting of adverse drug reactions. Drug Saf 32(1):19–31
21. Aung AK, Tang MJ, Adler NR, de Menezes SL, Goh MSY, Tee HW et al (2018) Adverse drug reactions reported by healthcare professionals: reaction characteristics and time to reporting. J Clin Pharmacol 58(10):1332–1339
22. Bergvall T, Norén GN, Lindquist M (2014) vigi Grade: a tool to identify well-documented individual case reports and highlight systematic data quality issues. Drug Saf 37(1):65–77
23. Wolf U, Baust H, Neef R, Steinke T. Individual Pharmacotherapy Management (IPM)-IV: Optimized Usage of Approved Antimicrobials Addressing Under-Recognized Adverse Drug Reactions and Drug-Drug Interactions in Polypharmacy. Antibiotics (Basel). 2022;11(10):1381. doi:10.3390/antibiotics11101381
24. López-Valverde L, Domènech È, Roguera M, Gich I, Farré M,Rodrigo C, et al. Spontaneous Reporting of Adverse Drug Reactions in a Pediatric Population in a Tertiary Hospital. J Clin Med. 2021;10(23):5531.
25. Shchory MP, Goldstein LH, Arcavi L, Shihmanter R, Berkovitch M, Levy A. Increasing adverse drug reaction reporting-How can we do better?. PLoS One. 2020;15(8):e0235591.
26. Jiang H, Lin Y, Ren W, Fang Z, Liu Y, Tan X, et al. Adverse drug reactions and correlations with drug-drug interactions: A retrospective study of reports from 2011 to 2020. FrontPharmacol. 2022 Aug 22;13:923939..
27. Palkovic B, Marchenko V, Zuperku EJ, Stuth EAE, Stucke AG. Multi Level Regulation of Opioid-Induced Respiratory Depression. Physiology (Bethesda). 2020;35(6):391-404.
28. Teoh CXW, Thng M, Lau S, Taing MW, Chaw SY, Siskind D, et al. Dry mouth effects from drugs used for depression, anxiety, schizophrenia and bipolar mood disorder in adults: systematic review. BJPsych.